Faculty Profiles

John Newman, MD, PhD

Assistant Professor

4150 Clement St
San Francisco, CA 94121
415-502-5134

Dr. Newman is a geriatrician, basic science researcher, and educator in the Division of Geriatrics at UCSF. As a physician-scientist, Dr. Newman hopes to translate what we are learning of the pathways that control fundamental mechanisms of aging into therapies that will improve the health and preserve the independence of older adults.


His research work is in the laboratory of Eric Verdin at the Gladstone Institutes, and focuses on how ketone bodies, small molecules that our bodies make for energy when we fast or exercise, also act as molecular signals to control inflammation and gene expression. The signaling functions of ketone bodies may be translational targets for protecting cognition and improving resilience in older adults. This is one example how environmental cues like diet and fasting signal through small metabolites in our cells to regulate the genes and pathways that in turn control aging. Dr. Newman is particularly interested in testing if harnessing these signals can protect older adults from the risks of hospitalization like delirium and functional decline.


Dr. Newman attends on the inpatient medicine service and the acute care of elders unit at the San Francisco VA Medical Center, with a clinical focus on delirium and functional decline. He teaches students, residents, and fellows about geriatric clinical problems, as well as about the biology of aging and emerging translational science in geriatrics. He works as a part of the national Geroscience Network to develop frameworks and resources for testing interventions that target fundamental mechanisms of aging in clinical trials. He seeks to bridge the community of basic scientists that study aging to geriatricians and other clinicians who study the clinical problems of aging in order to develop innovative translational therapies.


Dr. Newman completed an MD/PhD at the University of Washington in Seattle, then residency training in Internal Medicine and a fellowship in Geriatrics at UCSF before joining the faculty in 2014. Dr. Newman is a 2014 Beeson Scholar from the National Institute on Aging and the American Federation of Aging Research. His work has also been supported by generous funding from the Larry L. Hillblom Foundation and the Glenn Foundation for Medical Research.


Assistant Professor, Division of Geriatrics at UCSF
Visiting Scientist, Gladstone Institutes
Geriatrician, San Francisco VA Medical Center

Education and Training

Location Degree or Training Specialty Date
UCSF Fellowship Geriatric Medicine 2011
UCSF Residency Internal Medicine 2010
University of Washington MD/PhD Biochemistry 2008
Yale University BS/MS Molecular Biophysics and Biochemistry 2000

Interests

Geriatrics, acute care of elders, aging, dietary restriction, epigenetics, frailty, gene expression, ketone bodies, longevity, metabolism

Awards and Honors
2014   John S. Spice Award in Aging, Larry L. Hillblom Foundation, 2014
2014   Beeson Scholar, National Institute on Aging and American Federation for Aging Research, 2014-2019
2013   Award of Excellence in Scientific Leadership, Gladstone Institute of Virology and Immunology, 2013
2013   Glenn Award for Research in Biological Mechanisms of Aging, Paul F. Glenn Foundation, 2013
2012   Postdoctoral Fellowship, Larry L. Hillblom Foundation, 2012-2015
2011   Hartford Scholar, John A. Hartford Foundation, 2011-2013

Related Web Sites

Recent Articles (24)

Newman JC, Milman S, Hashmi SK, Austad SN, Kirkland JL, Halter JB, Barzilai N. Strategies and Challenges in Clinical Trials Targeting Human Aging. J Gerontol A Biol Sci Med Sci. 2016 Aug 16.

Justice J, Miller JD, Newman JC, Hashmi SK, Halter J, Austad SN, Barzilai N, Kirkland JL. Frameworks for Proof-of-Concept Clinical Trials of Interventions That Target Fundamental Aging Processes. J Gerontol A Biol Sci Med Sci. 2016 Aug 16.

Shirakawa K, Wang L, Man N, Maksimoska J, Sorum AW, Lim HW, Lee IS, Shimazu T, Newman JC, Schröder S, Ott M, Marmorstein R, Meier J, Nimer S, Verdin E. Salicylate, diflunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity. Elife. 2016; 5.

Newman JC, Steinman MA. Dextromethorphan-Quinidine for Agitation in Alzheimer Disease. JAMA. 2016 Mar 15; 315(11):1166.

Newman JC. Copyright and Bedside Cognitive Testing: Why We Need Alternatives to the Mini-Mental State Examination. JAMA Intern Med. 2015 Sep; 175(9):1459-60.

Newman JC, Verdin E. ß-hydroxybutyrate: much more than a metabolite. Diabetes Res Clin Pract. 2014 Nov; 106(2):173-81.

Rardin MJ, He W, Nishida Y, Newman JC, Carrico C, Danielson SR, Guo A, Gut P, Sahu AK, Li B, Uppala R, Fitch M, Riiff T, Zhu L, Zhou J, Mulhern D, Stevens RD, Ilkayeva OR, Newgard CB, Jacobson MP, Hellerstein M, Goetzman ES, Gibson BW, Verdin E. SIRT5 regulates the mitochondrial lysine succinylome and metabolic networks. Cell Metab. 2013 Dec 3; 18(6):920-33.

Newman JC, Verdin E. Ketone bodies as signaling metabolites. Trends Endocrinol Metab. 2014 Jan; 25(1):42-52.

Yee P, Newman J. Long-term outcomes in elderly survivors of cardiac arrest. N Engl J Med. 2013 Jun 20; 368(25):2438.

Rardin MJ, Newman JC, Held JM, Cusack MP, Sorensen DJ, Li B, Schilling B, Mooney SD, Kahn CR, Verdin E, Gibson BW. Label-free quantitative proteomics of the lysine acetylome in mitochondria identifies substrates of SIRT3 in metabolic pathways. Proc Natl Acad Sci U S A. 2013 Apr 16; 110(16):6601-6.

Feldman R, Newman J. Copyright at the Bedside: Should We Stop the Spread?. Stanford Technology Law Review. 2013; 16(3):623.

Shimazu T, Hirschey MD, Newman J, He W, Shirakawa K, Le Moan N, Grueter CA, Lim H, Saunders LR, Stevens RD, Newgard CB, Farese RV, de Cabo R, Ulrich S, Akassoglou K, Verdin E. Suppression of oxidative stress by ß-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science. 2013 Jan 11; 339(6116):211-4.

Newman JC, He W, Verdin E. Mitochondrial protein acylation and intermediary metabolism: regulation by sirtuins and implications for metabolic disease. J Biol Chem. 2012 Dec 14; 287(51):42436-43.

He W, Newman JC, Wang MZ, Ho L, Verdin E. Mitochondrial sirtuins: regulators of protein acylation and metabolism. Trends Endocrinol Metab. 2012 Sep; 23(9):467-76.

Bailey AD, Gray LT, Pavelitz T, Newman JC, Horibata K, Tanaka K, Weiner AM. The conserved Cockayne syndrome B-piggyBac fusion protein (CSB-PGBD3) affects DNA repair and induces both interferon-like and innate antiviral responses in CSB-null cells. DNA Repair (Amst). 2012 May 1; 11(5):488-501.

Newman JC, Feldman R. Copyright and open access at the bedside. N Engl J Med. 2011 Dec 29; 365(26):2447-9.

Frederick M, Newman J, Kohlwes J. Leriche syndrome. J Gen Intern Med. 2010 Oct; 25(10):1102-4.

Newman JC, Bailey AD, Fan HY, Pavelitz T, Weiner AM. An abundant evolutionarily conserved CSB-PiggyBac fusion protein expressed in Cockayne syndrome. PLoS Genet. 2008 Mar; 4(3):e1000031.

Cahan P, Rovegno F, Mooney D, Newman JC, St Laurent G, McCaffrey TA. Meta-analysis of microarray results: challenges, opportunities, and recommendations for standardization. Gene. 2007 Oct 15; 401(1-2):12-8.

Newman JC, Bailey AD, Weiner AM. Cockayne syndrome group B protein (CSB) plays a general role in chromatin maintenance and remodeling. Proc Natl Acad Sci U S A. 2006 Jun 20; 103(25):9613-8.

Newman JC, Weiner AM. L2L: a simple tool for discovering the hidden significance in microarray expression data. Genome Biol. 2005; 6(9):R81.

Newman JC, Weiner A. Measuring the immeasurable. Mol Cell. 2002 Sep; 10(3):437-9.

Schutzman JL, Borland CZ, Newman JC, Robinson MK, Kokel M, Stern MJ. The Caenorhabditis elegans EGL-15 signaling pathway implicates a DOS-like multisubstrate adaptor protein in fibroblast growth factor signal transduction. Mol Cell Biol. 2001 Dec; 21(23):8104-16.

  Select data provided by UCSF Profiles, powered by CTSI at UCSF. Learn more about the data source.